Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates
- PMID: 11883637
- DOI: 10.1023/a:1014216712820
Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates
Abstract
Purpose: To optimize the structure of geldanamycin (GDM) derivative moieties attached to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers via an enzymatically degradable spacer.
Methods: HPMA copolymers containing different AR-GDM (AR = 3-aminopropyl (AP), 6-aminohexyl (AH), and 3-amino-2-hydroxypropyl AP(OH)) were synthesized and characterized. Their cytotoxicity towards the A2780 human ovarian carcinoma cells was evaluated.
Results: The cytotoxic efficacy of HPMA copolymer-AR-GDM conjugates depended on the structure of AR-GDM. Particularly, HPMA copolymer-bound AH-GDM, which possessed the longest substituent at the 17-position, demonstrated the highest efficacy among the polymer-bound GDM derivatives; however the activity of free AH-GDM was lower than that of the other free AR-GDMs. The relative increase of the activity of macromolecular AH-GDM when compared to AP-GDM or AP(OH)-GDM correlated with the enhanced recognition of AH-GDM terminated oligopeptide side-chains by the active site of the lysosomal enzyme, cathepsin B. Drug stability and further stabilization upon binding to HPMA copolymer also contributed to the observed phenomena.
Conclusions: AH-GDM was found to be a suitable GDM derivative for the design of a drug delivery system based on HPMA copolymers and enzymatically-degradable spacers.
Similar articles
-
Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.Mol Pharm. 2009 Nov-Dec;6(6):1836-47. doi: 10.1021/mp900134c. Mol Pharm. 2009. PMID: 19743884 Free PMC article.
-
Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.Pharm Res. 2009 Jun;26(6):1407-18. doi: 10.1007/s11095-009-9851-0. Epub 2009 Feb 19. Pharm Res. 2009. PMID: 19225872 Free PMC article.
-
Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates.J Control Release. 2001 Jul 6;74(1-3):203-11. doi: 10.1016/s0168-3659(01)00318-2. J Control Release. 2001. PMID: 11489496
-
HPMA copolymer-cyclic RGD conjugates for tumor targeting.Adv Drug Deliv Rev. 2010 Feb 17;62(2):167-83. doi: 10.1016/j.addr.2009.11.027. Epub 2009 Dec 4. Adv Drug Deliv Rev. 2010. PMID: 19951733 Review.
-
Cytoplasmic delivery and nuclear targeting of synthetic macromolecules.J Control Release. 2003 Feb 21;87(1-3):89-105. doi: 10.1016/s0168-3659(02)00352-8. J Control Release. 2003. PMID: 12618026 Review.
Cited by
-
HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer.Pharm Res. 2010 Dec;27(12):2683-93. doi: 10.1007/s11095-010-0267-7. Epub 2010 Sep 16. Pharm Res. 2010. PMID: 20845065
-
In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer.Macromol Biosci. 2014 Dec;14(12):1735-47. doi: 10.1002/mabi.201400360. Epub 2014 Sep 4. Macromol Biosci. 2014. PMID: 25185891 Free PMC article.
-
Polymer nanomedicines.Adv Drug Deliv Rev. 2020;156:40-64. doi: 10.1016/j.addr.2020.07.020. Epub 2020 Jul 28. Adv Drug Deliv Rev. 2020. PMID: 32735811 Free PMC article. Review.
-
Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.Mol Pharm. 2009 Nov-Dec;6(6):1836-47. doi: 10.1021/mp900134c. Mol Pharm. 2009. PMID: 19743884 Free PMC article.
-
Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.Pharm Res. 2009 Jun;26(6):1407-18. doi: 10.1007/s11095-009-9851-0. Epub 2009 Feb 19. Pharm Res. 2009. PMID: 19225872 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous